Dynamic escape of pre-existing raltegravir-resistant HIV-1 from raltegravir selection pressure

Antiviral Res. 2010 Dec;88(3):281-6. doi: 10.1016/j.antiviral.2010.09.016. Epub 2010 Sep 29.

Abstract

Using quantitative deep HIV-1 sequencing in a subject who developed virological failure to deep salvage therapy with raltegravir, we found that most Q148R and N155H mutants detected at the time of virological failure originated from pre-existing minority Q148R and N155H variants through independent evolutionary clusters. Double 148R+N155H mutants were also detected in 1.7% of viruses at virological failure in association with E138K and/or G163R. Our findings illustrate the ability of HIV-1 to escape from suboptimal antiretroviral drug pressure through selection of pre-existing drug-resistant mutants, underscoring the importance of using fully active antiretroviral regimens to treat all HIV-1-infected subjects.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Amino Acid Sequence
  • Amino Acid Substitution* / drug effects
  • Amino Acid Substitution* / genetics
  • DNA Mutational Analysis
  • Drug Resistance, Viral* / drug effects
  • Drug Resistance, Viral* / genetics
  • HIV Infections / drug therapy*
  • HIV Infections / genetics*
  • HIV Infections / virology
  • HIV Integrase / metabolism
  • HIV Integrase Inhibitors / pharmacology*
  • HIV Integrase Inhibitors / therapeutic use*
  • HIV-1 / drug effects*
  • HIV-1 / enzymology
  • HIV-1 / genetics*
  • Humans
  • Male
  • Molecular Sequence Data
  • Mutation*
  • Phylogeny
  • Pyrrolidinones / pharmacology*
  • Pyrrolidinones / therapeutic use*
  • Raltegravir Potassium
  • Selection, Genetic* / drug effects
  • Treatment Failure

Substances

  • HIV Integrase Inhibitors
  • Pyrrolidinones
  • Raltegravir Potassium
  • HIV Integrase